Live tape
Top 8, mentions 7d15,267NVDA6,541 mentions▲ +0.04GOOGL1,865 mentions▲ +0.04SPY1,671 mentions▲ +0.05QQQ1,446 mentions▲ +0.05SPCX1,139 mentions▲ +0.06AMD950 mentions▲ +0.08MSFT842 mentions▲ +0.03CRWV813 mentions▲ +0.07

Equity · Healthcare

SGMT

NASDAQ

Sagimet Biosciences (SGMT)

7.83 USD +2.49% vs prior close
Sagimet Biosciences Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
335.9M USD
EPS, diluted, year to Dec 2025
−1.58 USD
52-week range
4.55 USD – 10.01 USD
Avg volume
250.2K

as of Jul 17, 2026

Have Sagimet Biosciences (SGMT) insiders bought or sold shares recently?

In the 90 days to 11 Nov 2026, Sagimet Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 4 Nov 2025, show no open-market purchase.

Form 4, 90 days to 11 Nov 2026, newest reported trade 14 Aug 2026

0buys
1sells
$3.59Mnet sold
1other filings
Have Sagimet Biosciences (SGMT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
14 Aug 2026Kemble GeorgeDirectorSell350,9873.6M USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Sagimet Biosciences (SGMT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
14 Aug 2026Kemble GeorgeDirectorOption exercise350,9872.2M USD

Which funds hold Sagimet Biosciences (SGMT)?

8 of the 45 institutional funds we track reported a Sagimet Biosciences position for the quarter ended 30 Jun 2026 — a combined 47.0M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Sagimet Biosciences (SGMT)?
FundPositionSharesValueShares q/q
Balyasny Asset ManagementNew position3,626,11328.0M USD
Baker Bros. AdvisorsHeld (±25%)952,9967.4M USD
Millennium ManagementHeld (±25%)937,0257.2M USD+8.7%
Renaissance TechnologiesTrimmed346,9272.7M USD−44.5%
Citadel AdvisorsAdded104,633809K USD+53.5%
Two Sigma InvestmentsAdded81,902633K USD+104.1%
D. E. Shaw & Co.Trimmed22,177171K USD−94.6%
Man GroupTrimmed13,856107K USD−74.2%
Marshall WaceExited
Point72 Asset ManagementExited

What has been filed or recorded for Sagimet Biosciences (SGMT)?

The filings we hold for Sagimet Biosciences, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Sagimet Biosciences (SGMT)?
And
13 Oct 2026Fails to deliverShares failed to deliver2,604 shares23K USD notional · 0.006% of shares out
01 Oct 2026Fails to deliverShares failed to deliver4,218 shares42K USD notional · 0.010% of shares out
30 Sep 2026Fails to deliverShares failed to deliver50 shares467 USD notional · <0.001% of shares out
28 Sep 2026Fails to deliverShares failed to deliver4,570 shares42K USD notional · 0.011% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.26 USD
30 Jun 2026FinancialsTotal assets263.4M USDat period end
30 Jun 2026FinancialsTotal equity256.2M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.33 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.58 USD
31 Dec 2025FinancialsNet income−51.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.58 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.40 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.32 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.56 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.45 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.45 USD

What do people ask about Sagimet Biosciences (SGMT)?

From live data
What is Sagimet Biosciences’ market cap?335.9M

Sagimet Biosciences is worth 335.9M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Sagimet Biosciences insiders bought or sold shares recently?1 sale

In the 90 days to 11 Nov 2026, Sagimet Biosciences insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 4 Nov 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Sagimet Biosciences?8 of 45

8 of the 45 funds we track reported a Sagimet Biosciences position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Balyasny Asset Management, Baker Bros. Advisors and Millennium Management. See Funds

When did Sagimet Biosciences last report earnings?−0.26

Sagimet Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.26 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings